Company Description
Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization.
The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities.
It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services.
The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024.
Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jul 24, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Jeffrey Alan Wolf J.D. |
Contact Details
Address: 627 Davis Drive, Suite 300 Morrisville, North Carolina 27560 United States | |
| Phone | 919-240-7133 |
| Website | scorpiusbiologics.com |
Stock Details
| Ticker Symbol | SCPX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001476963 |
| ISIN Number | US42237K4094 |
| Employer ID | 26-2844103 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey Alan Wolf J.D. | Founder, Chairman of the Board, Chief Executive Officer and President |
| William L. Ostrander | Chief Financial Officer and Secretary |
| Dr. Justin Stebbing FRCP, FRCPath, M.A., M.D., Ph.D. | Chief Medical Advisor and Member of Scientific and Clinical Advisory Board |
| Colonel George E. Peoples Jr., F.A.C.S., M.D. | Chief Medical Advisor |
| Ania Szymanska | Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2024 | 8-K | Current Report |
| May 29, 2024 | 8-K | Current Report |
| May 28, 2024 | 10-Q | Quarterly Report |
| May 24, 2024 | 8-K | Current Report |
| May 22, 2024 | 8-K | Current Report |
| May 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 16, 2024 | 8-K | Current Report |
| May 16, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 16, 2024 | 424B4 | Prospectus |
| May 16, 2024 | 424B4 | Prospectus |